Germany

Germany's modern psychedelic story is best understood through regulation and psychiatry rather than discovery chemistry. The decisive legal fact is that core classical psychedelics remain in Anlage I of the BtMG, which sharply restricts ordinary medical traffic and helps explain why psychedelic clinical work remained marginal for decades after the prohibition era. Even today, BfArM's compassionate use framework sits explicitly outside ordinary marketing authorisation. [1]BtMG Anlage I [2]BfArM Compassionate Use table

The modern re-entry came through academic psychopharmacology, neuroimaging and rapid-acting antidepressant research. An important adjacent development was esketamine. The European Medicines Agency authorised Spravato in 2019 for treatment-resistant depression, and the G-BA later noted that the medicine has been prescribable in Germany since 1 March 2021 under supervised psychiatric use. This gave German clinicians a lawful glutamatergic treatment route before any classical psychedelic reached even limited patient access. [3]EMA Spravato EPAR [4]G-BA esketamine benefit assessment

The most important Germany-specific research inflection point was EPIsoDE, launched in 2021 and led by the Central Institute of Mental Health in Mannheim with Charite in Berlin and the MIND Foundation as partners. The official federal project page lists BMBF/BMFTR grants of EUR 1,391,515 for ZI Mannheim under Gerhard Gruender and EUR 943,059 for Charite under Andreas Stroehle, making the initial public grant base about EUR 2.33 million before later extensions. In late 2022 the project received additional BMBF support of almost EUR 2.6 million, split at roughly EUR 2.3 million for Mannheim and EUR 300,000 for Berlin, to add biomarker, cost-effectiveness and acceptability work. [5]BMFTR EPIsoDE project page [6]ZI Mannheim EPIsoDE additional BMBF funding announcement [7]Charite Psychedelic Substances Research Group [8]MIND Foundation

The next step was pre-authorisation clinical access. On 31 July 2025, ZI Mannheim announced that Germany had secured the first psilocybin compassionate use programme in the European Union, with treatment in Mannheim and at OVID Clinic Berlin in justified exceptional cases. In March 2026, EPIsoDE then produced the first major published Germany-led randomised psilocybin depression outcome paper, moving the country from speculative promise to a clearer evidence-based position. [9]ZI Mannheim psilocybin compassionate use announcement [10]OVID Clinic Berlin psilocybin therapy page [11]JAMA Psychiatry EPIsoDE publication

Berlin is now the most concentrated psychedelic node in Germany because treatment, trials, training, and public discourse all intersect there. That matters for researchers and policy observers: Berlin is where Germany's most visible clinical-access experiment, most visible university pipeline, and most visible independent training organisation coexist. [1]OVID Clinic Berlin psilocybin therapy page [2]Charite Psychedelic Substances Research Group [3]MIND Foundation

According to OVID Clinic Berlin's own materials, the clinic is the Berlin treatment site inside the psilocybin compassionate use programme that was secured under the direction of Gerhard Gruender. OVID says the relevant licence has been delegated locally to Andrea Jungaberle and that treatment occurs in the day clinic, not as ordinary outpatient prescribing. OVID also presents itself as a private psychiatric-psychotherapeutic practice and day clinic serving privately insured patients and self-payers, which reinforces the point that this pathway is not general statutory care. This is an organisational source and should be read as such. [1]OVID Clinic Berlin psilocybin therapy page

The MIND Foundation gives Berlin a second role beyond treatment delivery. MIND describes itself as a Berlin-based nonprofit dedicated to research and education, as a partner of OVID Clinic Berlin, and as the operator of the 15-month Augmented Psychotherapy Training. It also runs science-communication and discourse formats such as the INSIGHT Forum. In practical terms, that makes MIND a training and convening institution in the Berlin ecosystem rather than a regulator, payer or market-authorisation holder. These are organisational sources. [3]MIND Foundation

Charite anchors Berlin's academic side. Official pages from its Psychedelic Substances Research Group show Berlin participation in EPIsoDE, completed COMP006 psilocybin work, completed BPL-003 5-MeO-DMT work, and completed MDMA-assisted psychotherapy feasibility work in PTSD. Charite also lists ongoing CYB003 and MM120 studies and non-trial projects such as PsychedELSI and PsyTrans. That combination gives Berlin unusual depth across efficacy, implementation, ethics and harm-related research. [2]Charite Psychedelic Substances Research Group

TRYP EXPO may be mentioned only as a future ecosystem signal. Official sources place its founding edition at Funkhaus Berlin on 15-17 May 2026. That indicates that Berlin is becoming a major meeting point for psychedelic science and adjacent sectors. It should not, however, be read as evidence of regulatory liberalisation, reimbursement progress or expanded patient access. [4]TRYP EXPO

The immediate regulatory question is not broad approval but continuity of the current exceptional pathway. BfArM's public table lists the psilocybin compassionate use programme only through 11 July 2026. Unless it is renewed or replaced, the publicly confirmed programme expires then. Even if extended, it would still remain a narrow cohort programme under compassionate use rules rather than a general prescribing route. [1]BfArM Compassionate Use table

The nearer-term research outlook is stronger than the access outlook. Berlin continues to host Charite participation in phase III CYB003 for depression and phase III MM120 for generalised anxiety disorder, while EPIsoDE investigators have publicly said that additional analyses on biomarkers and psychological mechanisms are still in preparation. The most explicit next-generation German ambition is DiMension: a planned phase III, HTA and approval study led by a consortium around MIND, SPRIND, Usona and ZI Mannheim, designed for more than 700 patients over 32 weeks. MIND describes it as still in preparation and to be funded through public sources and philanthropy, so no reliable public total budget should be treated as secured. [2]Charite Psychedelic Substances Research Group [3]JAMA Psychiatry EPIsoDE publication [4]MIND Foundation DiMension trial overview

Wider public reimbursement or routine clinical availability for a classical psychedelic still looks premature. The most plausible German route is the conventional one: marketing authorisation first, then G-BA evaluation and reimbursement negotiation, with DiMension showing how a future psilocybin programme might be designed for that pathway if funded. In other words, German psychedelic medicine is still moving through standard medicines regulation and health technology assessment, not around it. That makes the country highly credible scientifically, but still structurally cautious in access terms. [5]BtMG Anlage I [6]G-BA esketamine benefit assessment [4]MIND Foundation DiMension trial overview